Project #118:
Expected Background Rates of Clinical Events in Immunocompromised Patients

Alternatives to COVID vaccines are being developed for people whose immune system is compromised, and who therefore are unable to benefit from currently available vaccines. One example is Evusheld, a combination of two monoclonal antibodies, tixagevimab and cilgavimab. Once these treatments are launched, their safety will be closely monitored for example through spontaneous reporting of suspected adverse drug reactions by patients, carers and healthcare professionals. In order to contextualise potential safety signals arising from spontaneous reporting, a detailed understanding of the background rate of key clinical events in an immunocompromised population is required. This will help with the interpretation of potential signals, and to prioritise which studies should be done to further investigate signals. This study will therefore describe the underlying rate of key clinical outcomes in immunocompromised people in the UK.